HC Wainwright & Co. Reiterates Buy on Kymera Therapeutics, Maintains $46 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Kymera Therapeutics (NASDAQ:KYMR) and maintained a $46 price target.
June 17, 2024 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Kymera Therapeutics and maintained a $46 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $46 price target by a reputable analyst suggests positive sentiment and confidence in Kymera Therapeutics' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100